<DOC>
	<DOCNO>NCT00097916</DOCNO>
	<brief_summary>About 65 % patient severe Alzheimer 's Disease ( AD ) symptoms agitation . There drawback associate currently available therapeutic intervention agitation associate Alzheimer 's Disease . In recent trial , group patient moderate severe AD treat memantine , few incidence agitation . It hypothesize memantine effective reducing symptom agitation associate moderate severe Alzheimer 's Disease .</brief_summary>
	<brief_title>An Evaluation Safety Efficacy Memantine Agitated Patients With Moderate Severe Alzheimer 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Memantine</mesh_term>
	<criteria>Moderate Severe Alzheimer 's Disease score great equal 4 agitation/aggression domain NPI Stable dose donepezil 3 month Other evidence psychiatric disorder Oncologic diagnosis Clinically significant gastrointestinal , renal , hepatic , endocrine cardiovascular disease</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>memantine HCl</keyword>
	<keyword>Dementia</keyword>
	<keyword>Agitation</keyword>
	<keyword>Alzheimer Disease</keyword>
</DOC>